CY1124762T1 - Αναστολεις πρωτεïνης δεσμευσης creb (cbp) - Google Patents
Αναστολεις πρωτεïνης δεσμευσης creb (cbp)Info
- Publication number
- CY1124762T1 CY1124762T1 CY20211101010T CY211101010T CY1124762T1 CY 1124762 T1 CY1124762 T1 CY 1124762T1 CY 20211101010 T CY20211101010 T CY 20211101010T CY 211101010 T CY211101010 T CY 211101010T CY 1124762 T1 CY1124762 T1 CY 1124762T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cbp
- inhibitors
- family
- binding protein
- creb binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692593P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/051214 WO2019055869A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| PCT/US2018/051235 WO2019055877A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| US201962819490P | 2019-03-15 | 2019-03-15 | |
| US16/457,596 US10870648B2 (en) | 2018-06-29 | 2019-06-28 | Inhibiting CREB binding protein (CBP) |
| PCT/US2019/039936 WO2020006483A1 (en) | 2018-06-29 | 2019-06-28 | Inhibiting creb binding protein (cbp) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124762T1 true CY1124762T1 (el) | 2022-07-22 |
Family
ID=68987627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211101010T CY1124762T1 (el) | 2018-06-29 | 2021-11-22 | Αναστολεις πρωτεïνης δεσμευσης creb (cbp) |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10870648B2 (https=) |
| EP (1) | EP3998266A1 (https=) |
| JP (4) | JP6781806B2 (https=) |
| KR (2) | KR20250067962A (https=) |
| CN (2) | CN112513038B (https=) |
| AU (3) | AU2019295790B2 (https=) |
| BR (1) | BR112020026783A2 (https=) |
| CA (1) | CA3105099A1 (https=) |
| CY (1) | CY1124762T1 (https=) |
| DK (1) | DK3587418T3 (https=) |
| ES (1) | ES2900105T3 (https=) |
| HR (1) | HRP20211698T1 (https=) |
| HU (1) | HUE056885T2 (https=) |
| IL (3) | IL279734B2 (https=) |
| LT (1) | LT3587418T (https=) |
| MA (1) | MA50675B1 (https=) |
| MX (2) | MX2023013508A (https=) |
| PL (1) | PL3587418T3 (https=) |
| PT (1) | PT3587418T (https=) |
| RS (1) | RS62732B1 (https=) |
| SA (1) | SA520420909B1 (https=) |
| SG (1) | SG11202012767UA (https=) |
| SI (1) | SI3587418T1 (https=) |
| SM (1) | SMT202100636T1 (https=) |
| WO (1) | WO2020006483A1 (https=) |
| ZA (2) | ZA202100509B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279734B2 (en) * | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
| US12351577B2 (en) | 2019-03-15 | 2025-07-08 | Forma Therapeutics, Inc. | Inhibiting cyclic AMP-responsive element-binding protein (CREB) |
| AU2020241709B2 (en) * | 2019-03-15 | 2025-12-04 | Forma Therapeutics, Inc. | Compositions and methods for treating androgen receptor positive forms of cancer |
| IL299344A (en) | 2020-06-25 | 2023-02-01 | Tolremo Therapeutics Ag | Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer |
| AU2021298153A1 (en) | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | A combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for use in treating EGFR-mutant NSCLC |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| US5138089A (en) * | 1986-06-27 | 1992-08-11 | The Procter & Gamble Company | Chromophores, sunscreen compositions and methods for preventing sunburn |
| WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| JP5355838B2 (ja) | 2000-11-20 | 2013-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キラルな光異性化可能な化合物 |
| WO2003033517A1 (en) | 2001-10-17 | 2003-04-24 | The University Of British Columbia | Ship 1 modulators |
| AU2002349477A1 (en) | 2001-11-26 | 2003-06-10 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| IN2003CH00929A (https=) | 2003-11-13 | 2008-10-06 | ||
| US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
| WO2005099688A2 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| JP2009520038A (ja) | 2005-12-19 | 2009-05-21 | ジェネンテック・インコーポレーテッド | ピリミジンキナーゼインヒビター |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| CN101489544A (zh) | 2006-05-09 | 2009-07-22 | 海玛奎斯特医药公司 | 治疗血液病的方法 |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| CA2574531C (en) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| IN2014MN02330A (https=) | 2007-06-21 | 2015-08-14 | Wistar Inst | |
| WO2009000413A1 (en) | 2007-06-26 | 2008-12-31 | Sanofi-Aventis | A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| JP5223864B2 (ja) | 2007-06-27 | 2013-06-26 | 大正製薬株式会社 | １１β−ＨＳＤ１阻害活性を有する化合物 |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| AU2009330686B2 (en) | 2008-06-16 | 2014-07-03 | The Ohio State University Research Foundation | Compounds for the treatment of cancer |
| WO2010110380A1 (ja) * | 2009-03-27 | 2010-09-30 | 興和株式会社 | 縮合ピペリジン化合物及びこれを含有する医薬 |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| CN102459271B (zh) | 2009-04-15 | 2014-07-02 | Jw制药公司 | 回折模拟物的新化合物及其制备方法和用途 |
| CN102459248A (zh) | 2009-05-26 | 2012-05-16 | 埃克塞里艾克西斯公司 | 作为PI3K/mTOR抑制剂的苯并氧杂环庚三烯以及它们使用与制造方法 |
| WO2010138490A1 (en) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture |
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| MX2012010115A (es) | 2010-03-01 | 2013-02-26 | Gtx Inc | Compuestos para el tratamiento de cancer. |
| NZ603789A (en) * | 2010-05-26 | 2015-03-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| US8906943B2 (en) | 2010-08-05 | 2014-12-09 | John R. Cashman | Synthetic compounds and methods to decrease nicotine self-administration |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| EP2678050B1 (en) | 2011-02-24 | 2020-10-14 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| WO2013148114A1 (en) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| US9211333B2 (en) | 2012-06-05 | 2015-12-15 | Hong Kong Baptist University | Anti-cancer agents synthesized based on miliusane compounds |
| IN2015DN02008A (https=) | 2012-09-21 | 2015-08-14 | Advinus Therapeutics Ltd | |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| EP3010918B1 (en) | 2013-06-21 | 2018-08-15 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| CA2915838C (en) | 2013-06-21 | 2023-04-18 | Zenith Epigenetics Corp. | Bicyclic bromodomain inhibitors |
| AU2014292888B2 (en) | 2013-07-25 | 2018-03-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| DE102013215912B3 (de) | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
| JP6553632B2 (ja) | 2013-11-18 | 2019-07-31 | フォーマ セラピューティクス，インコーポレイテッド | Ｂｅｔブロモドメイン阻害剤としてのテトラヒドロキノリン組成物 |
| CN106029076B (zh) | 2013-11-18 | 2019-06-07 | 福马疗法公司 | 作为bet溴域抑制剂的苯并哌嗪组合物 |
| WO2016044694A1 (en) | 2014-09-19 | 2016-03-24 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
| US9763922B2 (en) | 2014-11-27 | 2017-09-19 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| EP3242878B1 (en) | 2015-01-08 | 2020-10-14 | Impetis Biosciences Ltd. | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| AU2017263574B2 (en) | 2016-05-12 | 2022-11-17 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| MA45122A (fr) | 2016-05-24 | 2019-04-10 | Constellation Pharmaceuticals Inc | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| EP3612522A4 (en) * | 2017-04-18 | 2021-07-07 | Celgene Quanticel Research, Inc. | THERAPEUTIC COMPOUNDS |
| US11292791B2 (en) * | 2017-09-15 | 2022-04-05 | Forma Therapeutics, Inc. | Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors |
| IL279734B2 (en) * | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
-
2019
- 2019-06-28 IL IL279734A patent/IL279734B2/en unknown
- 2019-06-28 CN CN201980050022.XA patent/CN112513038B/zh active Active
- 2019-06-28 BR BR112020026783-0A patent/BR112020026783A2/pt unknown
- 2019-06-28 CA CA3105099A patent/CA3105099A1/en active Pending
- 2019-06-28 MX MX2023013508A patent/MX2023013508A/es unknown
- 2019-06-28 IL IL321337A patent/IL321337A/en unknown
- 2019-06-28 CN CN202211658329.8A patent/CN116178369A/zh active Pending
- 2019-06-28 MX MX2020014303A patent/MX2020014303A/es unknown
- 2019-06-28 KR KR1020257014745A patent/KR20250067962A/ko active Pending
- 2019-06-28 KR KR1020217002866A patent/KR102805503B1/ko active Active
- 2019-06-28 US US16/457,596 patent/US10870648B2/en active Active
- 2019-06-28 IL IL313466A patent/IL313466B2/en unknown
- 2019-06-28 SG SG11202012767UA patent/SG11202012767UA/en unknown
- 2019-06-28 AU AU2019295790A patent/AU2019295790B2/en active Active
- 2019-06-28 WO PCT/US2019/039936 patent/WO2020006483A1/en not_active Ceased
- 2019-07-01 EP EP21193994.7A patent/EP3998266A1/en active Pending
- 2019-07-01 LT LTEP19183741.8T patent/LT3587418T/lt unknown
- 2019-07-01 DK DK19183741.8T patent/DK3587418T3/da active
- 2019-07-01 HR HRP20211698TT patent/HRP20211698T1/hr unknown
- 2019-07-01 SI SI201930136T patent/SI3587418T1/sl unknown
- 2019-07-01 PL PL19183741T patent/PL3587418T3/pl unknown
- 2019-07-01 PT PT191837418T patent/PT3587418T/pt unknown
- 2019-07-01 MA MA50675A patent/MA50675B1/fr unknown
- 2019-07-01 RS RS20211321A patent/RS62732B1/sr unknown
- 2019-07-01 ES ES19183741T patent/ES2900105T3/es active Active
- 2019-07-01 HU HUE19183741A patent/HUE056885T2/hu unknown
- 2019-07-01 SM SM20210636T patent/SMT202100636T1/it unknown
- 2019-07-01 JP JP2019123100A patent/JP6781806B2/ja active Active
-
2020
- 2020-05-28 JP JP2020093126A patent/JP7017801B2/ja active Active
- 2020-06-08 US US16/946,159 patent/US11254674B2/en active Active
- 2020-12-17 JP JP2020209005A patent/JP2021042255A/ja not_active Withdrawn
- 2020-12-28 SA SA520420909A patent/SA520420909B1/ar unknown
-
2021
- 2021-01-25 ZA ZA2021/00509A patent/ZA202100509B/en unknown
- 2021-11-22 CY CY20211101010T patent/CY1124762T1/el unknown
-
2022
- 2022-02-10 US US17/669,112 patent/US12378242B2/en active Active
- 2022-09-23 ZA ZA2022/10560A patent/ZA202210560B/en unknown
-
2023
- 2023-09-05 AU AU2023226653A patent/AU2023226653B2/en active Active
-
2025
- 2025-03-21 JP JP2025046918A patent/JP2025094157A/ja active Pending
- 2025-07-29 AU AU2025210762A patent/AU2025210762A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124762T1 (el) | Αναστολεις πρωτεïνης δεσμευσης creb (cbp) | |
| CY1126132T1 (el) | Πυριδαζινονες ως αναστολεις parp7 | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| JOP20210193A1 (ar) | مثبطات pcsk9 وطرق استخدامها | |
| EP3773726C0 (en) | TREATMENT OF TUMORS WITH TTFIELDS AND AN AURORA KINASE INHIBITOR | |
| JOP20200209A1 (ar) | مثبطات cd73 | |
| EA202092086A1 (ru) | Ингибиторы аргиназы | |
| AU2018278311A1 (en) | IRE1 small molecule inhibitors | |
| EA201890730A1 (ru) | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования | |
| EA201890325A1 (ru) | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний | |
| JOP20230170A1 (ar) | مثبطات cdk2 وطرق لاستخدامها | |
| EA201792229A1 (ru) | Ингибиторы бромодомена | |
| EA201891974A1 (ru) | Ингибиторы связывания белка wdr5 с белками | |
| EA201892229A1 (ru) | Замещенные аминопуриновые соединения, содержащие их композиции и способы лечения с их применением | |
| EA202190749A1 (ru) | Способы комбинированной терапии | |
| EA202091803A1 (ru) | Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) | |
| EA201791946A1 (ru) | Лечение хронической реакции "трансплантат против хозяина" с применением ингибиторов syk | |
| BR112022008821A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| EA201990418A1 (ru) | Производные оксадиазолопиридина для применения в качестве ингибиторов грелин-о-ацилтрасферазы (goat) | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| EA202091804A1 (ru) | Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) | |
| MX2023000332A (es) | Heterociclos triciclicos. | |
| MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
| EA202190103A1 (ru) | Трициклические соединения |